Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 117976-90-6 | Product Number: R0115
Rabeprazole Sodium Salt
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 100MG |
$119.00
|
Contact Us | 1 | 12 |
|
| 1G |
$490.00
|
Contact Us | 1 | 13 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0115 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__8H__2__0N__3NaO__3S = 381.43 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Hygroscopic,Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 117976-90-6 |
| Related CAS RN | 117976-89-3 |
| Reaxys Registry Number | 7561607 |
| PubChem Substance ID | 253660182 |
| Merck Index (14) | 8089 |
| MDL Number | MFCD02092688 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 95.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 150 °C |
| Solubility (soluble in) | Methanol |
| Solubility (insoluble in) | Ether |
GHS
Related Laws:
Transport Information:
| HS Number | 2933.99.9701 |
Application
A More Potent Proton Pump Inhibitor, Rabeprazole Sodium
Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pump inhibitors. Rabeprazole sodium is a more potent inhibitor of H+,K+-ATPase (hydrogen-potassium adenosine triphosphatase) and acid secretion than omeprazole [O0359], and is a more rapid inhibitor of proton pumps than omeprazole, lansoprazole [L0233], or pantoprazole sulfide [P2066]. Furthermore, in vitro studies have shown that rabeprazole sodium possesses more potent antibacterial properties against the growth of H. pylori than other proton pump inhibitors.
References
- The pharmacology of rabeprazole
- Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
- Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study
- Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH
- In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates of Helicobacter pylori
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.